Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

akebia therapeutics inc. - AKBA

AKBA

Close Chg Chg %
3.69 0.28 7.59%

Closed Market

3.97

+0.28 (7.59%)

Volume: 8.18M

Last Updated:

Jun 6, 2025, 4:00 PM EDT

Trade Now

Company Overview: akebia therapeutics inc. - AKBA

AKBA Key Data

Open

$3.66

 Day Range

3.66 - 4.00

52 Week Range

0.80 - 4.00

 Market Cap

$969.13M

Shares Outstanding

262.64M

 Public Float

251.86M

Beta

0.85

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.21

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

5.97M

  

AKBA Performance

1 Week
 
 31.02%
 
1 Month
 
 55.69%
 
3 Months
 
 108.95%
 
1 Year
 
 274.53%
 
5 Years
 
 -66.79%
 

AKBA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About akebia therapeutics inc. - AKBA

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

AKBA At a Glance

Akebia Therapeutics, Inc.
245 First Street
Cambridge, Massachusetts 02142
Phone 1-617-871-2098 Revenue 160.18M
Industry Pharmaceuticals: Major Net Income -69,410,000.00
Sector Health Technology Employees 181
Fiscal Year-end 12 / 2025
View SEC Filings

AKBA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.502
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -62.395
Enterprise Value to Sales 3.394
Total Debt to Enterprise Value 0.358

AKBA Efficiency

Revenue/Employee 884,972.376
Income Per Employee -383,480.663
Receivables Turnover 4.661
Total Asset Turnover 0.693

AKBA Liquidity

Current Ratio 1.407
Quick Ratio 1.206
Cash Ratio 0.641

AKBA Profitability

Gross Margin 57.025
Operating Margin -31.473
Pretax Margin -43.333
Net Margin -43.333
Return on Assets -30.023
Return on Equity N/A
Return on Total Capital -47.715
Return on Invested Capital -77.384

AKBA Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 133.812
Total Debt to Total Assets 88.21
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 123.062
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Akebia Therapeutics Inc. - AKBA

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
213.58M 292.48M 194.62M 160.18M
Sales Growth
-27.68% +36.94% -33.46% -17.70%
Cost of Goods Sold (COGS) incl D&A
155.32M 87.22M 75.73M 68.84M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
36.13M 35.28M 41.85M 41.70M
Depreciation
85.00K (763.00K) 5.80M 5.66M
Amortization of Intangibles
36.04M 36.04M 36.04M 36.04M
COGS Growth
-14.87% -43.84% -13.17% -9.11%
Gross Income
58.26M 205.26M 118.89M 91.34M
Gross Income Growth
-48.38% +252.34% -42.08% -23.17%
Gross Profit Margin
+27.28% +70.18% +61.09% +57.03%
2021 2022 2023 2024 5-year trend
SG&A Expense
323.57M 270.11M 164.96M 141.76M
Research & Development
145.93M 128.33M 61.49M 31.99M
Other SG&A
177.65M 141.78M 103.47M 109.77M
SGA Growth
-13.43% -16.52% -38.93% -14.07%
Other Operating Expense
- - - -
-
Unusual Expense
(600.00K) 17.90M 1.47M 905.00K
EBIT after Unusual Expense
(264.72M) (82.75M) (47.54M) (51.32M)
Non Operating Income/Expense
1.81M 4.21M 1.65M 94.00K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
19.94M 15.69M 6.03M 18.18M
Interest Expense Growth
+124.73% -21.31% -61.55% +201.48%
Gross Interest Expense
19.94M 15.69M 6.03M 18.18M
Interest Capitalized
- - - -
-
Pretax Income
(282.84M) (94.23M) (51.92M) (69.41M)
Pretax Income Growth
+26.24% +66.69% +44.89% -33.67%
Pretax Margin
-132.43% -32.22% -26.68% -43.33%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(282.84M) (94.23M) (51.92M) (69.41M)
Minority Interest Expense
- - - -
-
Net Income
(282.84M) (94.23M) (51.92M) (69.41M)
Net Income Growth
+26.24% +66.69% +44.89% -33.67%
Net Margin Growth
-132.43% -32.22% -26.68% -43.33%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(282.84M) (94.23M) (51.92M) (69.41M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(282.84M) (94.23M) (51.92M) (69.41M)
EPS (Basic)
-1.7044 -0.5155 -0.277 -0.329
EPS (Basic) Growth
+38.46% +69.75% +46.27% -18.77%
Basic Shares Outstanding
165.95M 182.78M 187.47M 210.95M
EPS (Diluted)
-1.7044 -0.5155 -0.277 -0.329
EPS (Diluted) Growth
+38.46% +69.75% +46.27% -18.77%
Diluted Shares Outstanding
165.95M 182.78M 187.47M 210.95M
EBITDA
(229.19M) (29.57M) (4.23M) (8.71M)
EBITDA Growth
-0.82% +87.10% +85.70% -106.01%
EBITDA Margin
-107.31% -10.11% -2.17% -5.44%

Snapshot

Average Recommendation BUY Average Target Price 7.30
Number of Ratings 5 Current Quarters Estimate -0.014
FY Report Date 06 / 2025 Current Year's Estimate -0.064
Last Quarter’s Earnings 0.03 Median PE on CY Estimate N/A
Year Ago Earnings -0.33 Next Fiscal Year Estimate 0.074
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 5 5
Mean Estimate -0.01 -0.04 -0.06 0.07
High Estimates 0.00 -0.02 -0.02 0.42
Low Estimate -0.04 -0.05 -0.11 -0.32
Coefficient of Variance -108.33 -37.27 -64.99 355.31

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 4
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Akebia Therapeutics Inc. - AKBA

Date Name Shares Transaction Value
Jul 3, 2024 Erik John Ostrowski SVP, CFO, CBO & Treasurer 350,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Erik John Ostrowski SVP, CFO, CBO & Treasurer 500,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 Michael W. Rogers Director 126,029 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 Michael W. Rogers Director 45,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 Adrian Adams Director 164,800 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 Adrian Adams Director 45,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 LeAnne M. Zumwalt Director 73,700 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 LeAnne M. Zumwalt Director 45,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 Steven C. Gilman Director 117,130 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 Steven C. Gilman Director 45,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 Ronald E. Frieson Director 73,700 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 Ronald E. Frieson Director 45,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 Cynthia Smith Director 125,233 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 Cynthia Smith Director 45,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 Myles Wolf Director 97,681 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 11, 2024 Myles Wolf Director 45,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Akebia Therapeutics Inc. in the News